1988
DOI: 10.1093/jnci/80.12.959
|View full text |Cite
|
Sign up to set email alerts
|

Transplantation Resistance to a Rous Sarcoma Virus-Induced Tumor in Mice Immunized With v-src Protein1

Abstract: It is of great interest in tumor immunology to know whether oncogene products could be used not only as tumor markers for cancer diagnosis, but also as immunogens for cancer therapy. BALB/c mice immunized with syngeneic fibroblasts, Escherichia coli cells producing p60v-src, or the purified p60v-src protein extracted from the E. coli producer cells showed transplantation resistance to a Rous sarcoma virus-induced tumor but not a Kirsten sarcoma virus-induced tumor. In contrast, mice immunized with cells not pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1992
1992
1996
1996

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Preinfection with src mutants that encode normal N termini and induce slow-growing tumors failed to elicit a protective effect. On the contrary, the v-src gene product has been shown to induce transplantation resistance to RSV-transformed mouse cells not producing infectious virus (Kuzumaki et al 1988;Suda et al 1988). Whether such resistance can be detected in chickens carrying a favorable haplotype will be tested, using transplantable syngeneic LTR, v-src, LTR tumor lines for challenge.…”
Section: Discussionmentioning
confidence: 99%
“…Preinfection with src mutants that encode normal N termini and induce slow-growing tumors failed to elicit a protective effect. On the contrary, the v-src gene product has been shown to induce transplantation resistance to RSV-transformed mouse cells not producing infectious virus (Kuzumaki et al 1988;Suda et al 1988). Whether such resistance can be detected in chickens carrying a favorable haplotype will be tested, using transplantable syngeneic LTR, v-src, LTR tumor lines for challenge.…”
Section: Discussionmentioning
confidence: 99%